Each trial was registered with ClinicalTrials.gov: identifiers NCT03954834, NCT03987919, NCT03882970, NCT03730662, and NCT04039503
It has a boxed warning for: Risk of thyroid C-cell tumors (seen in rats) Human risk is unknown, but monitor for thyroid symptoms.[accessdata.fda] Should I Keep Track of My Progress
Understand your cravings
Understanding the tirzepatide dosage mechanics helps you appreciate why the transition period is not immediate but also not infinitely long
A personal or family history of medullary thyroid carcinoma Multiple Endocrine Neoplasia syndrome type 2 A history of pancreatitis or gallbladder disease Kidney problems or previous dehydration Diabetic retinopathy Severe digestive disorders, reflux, nausea, or vomiting Pregnancy plans or a suspected pregnancy Insulin, sulfonylureas, oral contraceptives, and all other medications A supervised plan can help match dosing, nutrition, symptom monitoring, and follow-up to the individual rather than treating every patient the same way
Your specific options are discussed during your consultation